BioSpace News Archive

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, to be held on October 1-4, 2023 in Toronto, ON, Canada.

Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in the U.K. for Nymozarfex (TM) for the treatment of benign prostatic hyperplasia (BPH).

Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. announces that the Extraordinary General Meeting of Shareholders has adopted all proposals on the EGM agenda.

AcuraStem announced today that it has entered into a license agreement with Takeda to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) announces that, further to its press release of August 31, 2023, its management information circular (the “Circular”) and related materials were mailed today,

Theratechnologies Inc. today announced that it has reached an agreement in principle to amend some of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time (the “Loan Facility”), with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).

Kintara Therapeutics, Inc. today announced the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam.

Zucara Therapeutics Inc., today announced that it has dosed the first patient in its Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes (“T1D”) mellitus (“ZONE”).

MMI, a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, announced the successful completion of over 500 in-human surgeries with the Symani® Surgical System in the European Union.